Background: In the absence of unified treatment protocol, we evaluated the management and outcomes of submandibular gland cancers in an unselected patient series.
| I NT ROD UCTI ON
Submandibular gland tumors are rare, accounting for 7%-11% of salivary gland neoplasms, 1, 2 where 30%-54% are malignant. [1] [2] [3] [4] The 2017 World Health Organization (WHO)
classification divides salivary gland carcinomas into 20 different histological types, some of which are further divided into subtypes. 1 Thus, the diagnostics and treatment of salivary gland carcinomas differ from other head and neck carcinomas, of which over 90% are squamous cell carcinomas (SCCs). Mucoepidermoid carcinoma (MEC) and adenoid cystic carcinoma (ACC) are among the most frequent malignancies encountered in the major salivary glands. 5 Treatment recommendations for salivary gland carcinomas are usually based on parotid gland tumors. Still, the biological behaviors of parotid and submandibular gland tumors can vary.
The treatment of submandibular gland tumors remains challenging because the exact nature of the lesion is often unknown before or at the time of surgery. Inflammatory lesions are common and generally easy to differentiate from neoplasms using patient history, clinical examination, and ultrasound. Sometimes, inflammatory diseases, such as sclerosing sialadenitis, can resemble a malignant tumor. In the presence of neoplastic lesions, differentiating between benign and malignant lesions is often difficult. Because the histology of the tumor is seldom known preoperatively, the extent of surgical treatment to the neck is especially difficult to plan. We previously evaluated the treatment plans of all submandibular gland tumors at our institution during an 11-year period, and identified the challenges in differentiating between benign and malignant tumors. 4 In our series, 30% of submandibular gland tumors were malignant. We found fineneedle aspiration cytology (FNAC) under ultrasound guidance beneficial in treatment planning, while also considering its well-known limitations. Inadequate preoperative planning led to the need for additional surgeries when the histopathological examination revealed malignancy. Among all patients with a neoplasm, regional metastases were encountered in 6% of cases, that is, in 20% of malignancies.
Given the above, it seems obvious that applying generally accepted treatment guidelines could optimize the management of submandibular gland tumors. In the present study, we evaluate the treatment and outcome of submandibular gland cancers.
| P A TI ENT S A ND M ETHO DS
We included all patients who had undergone surgery at our institution for a malignant submandibular gland tumor between January 1, 2000, and December 31, 2010. Patient demographics, treatment, and follow-up data for 25 eligible patients were reviewed after January 1, 2017. We collected data on patient history, symptoms, clinical signs, imaging, FNAC, surgery, histopathological examination, pathologic TNM classification, 6 oncologic treatment, and follow-up. No other submandibular gland malignancies were diagnosed or treated at other hospitals within our university hospital district, which covers a population of 1.6 million people. The research ethics committee at the Helsinki University Hospital approved the study design and institutional research permission was granted. We reevaluated and compared the histopathological specimens and MRI scans with the original pathological and imaging data. The criteria for malignancy, which is described elsewhere, were used to reevaluate the MRI scans. 7 All patients had a minimum follow-up of 5 years or until death.
For statistical analyses, we used the IBM SPSS version 20.0 (SPSS, Chicago, IL). The 5-year overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) figures were calculated using the Kaplan-Meier estimate. The length of follow-up was calculated starting from the last day of treatment through the end of follow-up or death from any cause (OS) and disease-specific death (DSS). The length of DFS was calculated starting from the last treatment day through the detection of cancer recurrence at any site or death.
| RES U LTS
Our study population of 25 patients included 12 men (48%) and 13 women (52%) with a mean age of 59.6 years (range 26-88 years). The tumor characteristics are provided in Table  1 . Due to the variety of tumors and their treatment, patient data are shown in Table 2 .
The histological type did not change upon reevaluation in any of the cases. The most common histological type was ACC (14/25; 56%), followed by 6 other histological categories. Two tumors, both more than 2 cm in diameter, were 
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. . . reclassified as in situ carcinomas (stage 0)-both were within pleomorphic adenoma with an intact capsule. Both patients with SCC were initially identified as having unknown primaries, but the final histopathological examination of the neck dissection specimen revealed a tumor originating from the submandibular gland without any another detectable primary site.
The majority of the tumors were diagnosed at an early stage: 16 (16/25; 64%) were stage 0 to II, and altogether tumors in 20 patients (20/25; 80%) were classified as T in situ, T1, or T2 tumors. Histopathological examination revealed metastatic lymph nodes (pN1) in 5 patients (5/25; 20%). In addition, 20 patients (20/25; 80%) showed no neck metastases, 17 of which were verified from neck dissection specimens and 3 were clinically N0 (cN0) without recurrence through follow-up.
| Symptoms and clinical signs
The most common finding was a symptomless mass, in which palpation revealed only a single lump in 21 patients (21/25; 84%). Obvious malignancy was suspected in 3 cases (3/25; 12%): 1 patient had 2 palpable lumps, whereas 2 patients presented with a tumor growth (both SCCs) that raised suspicion. No patients had neurological symptoms or lingual, hypoglossal, or facial nerve functional deficits, and 21 patients (21/25; 84%) reported no pain. The average time interval between appearance of the mass and attendance at the clinic varied from an incidental finding to 10 years (<3 months, n 5 7; 3-6 months, n 5 5; about 1 year, n 5 4; and 2-10 years, n 5 9).
| Imaging
All patients underwent ultrasound and ultrasound-guided FNAC. The ultrasounds showed (1) a solid tumor with regular borders (13/25; 52%); (2) irregular borders (4/25; 16%); (3) a cystic-solid lesion (3/25; 12%); or (4) a highly vascularized lesion with low echogenicity (2/25; 8%). All 3 patients with obvious clinical findings for malignancy also showed malignant signs upon ultrasound. Abnormal or enlarged lymph nodes were reported in 6 patients, with pN 1 in 3 patients (3/25; 12%).
The MRI scans were performed on 15 patients (15/25; 60%) and 2 patients (2/25; 8%) underwent CT scans. The main indications included clinical signs of malignancy, FNAC classes 0, III, IV, and V, and/or suspicion of malignancy upon ultrasound. In 1 patient, the tumor was an incidental finding upon CT.
The primary MRI reports identified 2 tumors as benign, and 5 tumors as malignant, but provided no definitive statement about the tumors in the remaining 8 patients. In the neck, MRI showed suspicious lymph nodes in 5 patients, 4 of whom (4/25; 16%) had pN1. 
| 157
Reevaluation of the MRI scans was possible in 12 cases showing signs of potential malignancy as follows: T2 hypointensity in 6 patients (all after FNAC), irregular margins in 8 patients, extraglandular growth in 5 patients, and perineural growth in 1 patient. Pathological lymph nodes were noted in 4 patients (these same 4 patients were also correctly diagnosed in the primary reports). At least 1 of the abovementioned signs was present in 11 of 12 reevaluated tumors, and 10 tumors presented with at least 2 MRI signs of potential malignancy.
| Primary surgery
All 25 patients underwent surgery with a curative intent. Among the 11 patients (11/25; 44%) who only had the gland removed primarily without neck dissection, 8 did not present with any indications of possible malignancy, whereas 3 had class III upon FNAC. Furthermore, 14 patients (14/25; 56%) also had neck dissection primarily (Table 2 ). Frozen section analysis was used for 8 patients (8/25; 32%), and malignancy was indicated in all but 1.
| Additional surgery and neck metastases
The tumor board recommended additional surgery for 10 patients (10/25; 40%) due to inadequate margins or the type of histology or both. Eight of these patients previously underwent removal of the gland only without neck dissection. The specimens from the subsequent surgeries revealed remaining carcinoma in 5 patients (5/10; 50%) at the primary site, and pN 1 in only 1 patient with salivary duct carcinoma.
Including the additional surgeries in our analysis, we found that 22 patients (22/25; 88%) ultimately underwent at least levels I to III neck dissection. The exact levels of the metastatic lymph nodes remained unknown because the levels were unmarked in the dissection specimens. All 5 patients (5/25; 20%) with pN 1 had at least 2 ipsilateral metastases (pN2b). Only 1 patient (with SCC) had occult metastases, yielding an occult metastatic rate of 4% (1/25). Among ACCs, only 1 patient (1/14; 7%) had pN1.
| Oncologic treatment for primary tumors
Postoperative radiotherapy (RT) was given to 15 patients (15/ 25; 60%) with an average dose of 60 Gy (range 50-70 Gy). Among these 15 patients, 3 had salivary duct carcinomas and received cisplatin 40 mg/m 2 once weekly as concomitant chemotherapy together with RT (chemoradiotherapy [CRT]). The RT was administered using a linear accelerator with 6 MV photons. A thermoplastic head and neck mask was used for immobilization. Five patients were treated using conventional 3D RT, and 10 patients received intensity-modulated radiotherapy. The clinical target volume encompassed the surgical bed of the submandibular gland with wide margins, and 14 patients also received a total dose of up to 50 Gy at the ipsilateral neck. All patients were treated with conventional 2 Gy daily fractions administered 5 times a week.
| Recurrent tumors and follow-up
No patients were lost to follow-up, and the median follow-up time for patients alive at the end of the follow-up period was 9.0 years (range 5.0-16.0 years). Locoregional recurrences occurred in 4 patients (4/25; 16%) within a median of 0.6 years (range 0.1-2.2 years). Three of these patients received further treatment with a curative intent and all subsequently died with disease. Distant metastasis in the lungs or liver without locoregional recurrence was encountered in 7 patients (7/25; 28%) within a median of 4.6 years (range 0.1-8.8 years).
Of the 14 patients with ACC, 6 experienced recurrence during follow-up. Two tumors recurred locoregionally and 4 patients developed distant metastasis in the lungs or liver within a median of 4.7 years (range 0.5-8.8 years).
The 5-year DSS and OS rates were both 76%, and the DFS rate was 68%.
| DI S CU S S IO N
This study included all malignant submandibular gland tumors diagnosed and treated during an 11-year period within a catchment area of 1.6 million people in Southern Finland, 8 all treated at a single university hospital. We previously reported that malignant submandibular gland tumors represented 30% of all submandibular gland neoplasms in our study, 4 somewhat lower than typically reported, 2,3 yet in line with a more recent study. 9 Comparable with other reports, 9-12 most malignant tumors in our study were ACCs (56%). Reflecting our results, Han et al 10 found that salivary duct carcinoma (22%) and carcinoma ex pleomorphic adenoma (17%) were the next most common histological types encountered in submandibular gland malignancies. In addition to ACC, MEC and acinic cell carcinoma are among the most common histological types in parotid gland cancers. 13 Although 36% of the patients in the present study sought medical attention more than a year after the onset of symptoms-which is not uncommon 14 -most tumors (64%) were still diagnosed at an early stage (stages 0-II), unlike the findings reported by others. 10, 11 This may partially explain the somewhat surprising finding that only 3 patients had symptoms or clinical signs arousing suspicion of malignancy, and the most common finding of a symptomless mass only. This is in line with other studies, which showed that, in patients with ACC, a mass is the most common symptom, occurring in 77% 14 to 98% 15 of cases. Pain was reported by 48% of patients with ACC in a study by Nascimento et al, 15 whereas
another study found that only 7% of patients reported experiencing pain. 16 An MRI or CT was used in 68% of the present patients. In our limited sample, MRI provided a somewhat higher accuracy estimating the cervical lymph node status compared to ultrasound. Particularly noteworthy, unlike ultrasound, at our institution, dedicated head and neck radiologists perform most MRI studies, possibly contributing to these results. An unblinded second review of an MRI revealed some signs of potential malignancy in all but 1 of the 12 reevaluated scans. None of the available scans included modern techniques, such as diffusion-weighted imaging, dynamic contrastenhancement, or proton magnetic resonance spectroscopy, possibly further increasing the diagnostic accuracy of differentiating benign from malignant tumors. [17] [18] [19] [20] In our recent publication, which also included benign submandibular gland tumors, we discussed the role of ultrasound and MRI in the diagnosis of submandibular gland lesions. 4 Because the histology is seldom known at the time of surgery, treatment of the neck remains a challenge, especially in cases with cN0. The diagnosis of ACC generally does not call for elective neck dissection (END), 10, 14 in contrast to salivary duct carcinoma. [21] [22] [23] Still, some recommend END for all patients with salivary gland carcinoma. 24 The rate of neck metastases in samples, including all submandibular gland cancers, varies. For instance, some studies report high figures of up to 45% 10 and 50%, 24 whereas we found a rate of 20%.
Furthermore, our cohort included many patients at an early stage of disease. The rate of occult metastases also varies across studies. In addition to the different tumor stages and histologies reported between studies, the rate of occult metastases obviously depends on the diagnostic imaging methods. A study by Han et al 10 reported an occult metastatic rate of 20% among patients with submandibular gland cancer. Most specialists recommend END for all high-grade tumors, 5, 10, 25 excluding ACC, 10 which is in line with our study because ACCs carried a metastatic rate of only 7%. Hirvonen et al 16 found that 12% of patients with major salivary gland ACC presented with pN1. In their study, the occult metastatic rate was only 4%, despite that the study consisted of an older patient population treated when modern imaging methods were unavailable. 16 Similarly, Cohen et al 14 reported no occult metastases in submandibular gland ACC. By contrast, among all salivary gland carcinomas, Yoo et al 5 reported
occult metastases in 19% of ACCs.
Including routine neck dissection in all cases would result in overtreatment, because most submandibular gland tumors are benign, ACC is the most common malignant tumor, and occult metastases are uncommon. Still, including additional surgeries, most of our patients with malignancy underwent level IB or more extensive neck dissection, a commonly reported tendency in retrospective studies of ACC.
14, 16 We suggest that eventual neck dissection and its extent should be planned based on the cytological and radiological findings. Whenever malignancy is suspected (class III cytology or other criteria), we recommend extending surgery, at least to level IB, or to levels I to III depending on the case. Frozen section analysis can also prove useful in planning the extent of surgery, especially on the neck. 4, 24, 26 Among 10 patients (40%) in our cohort, additional surgery revealed remaining malignant tissue in 5 patients, but pN 1 was found in only 1 patient. Some argue that the surgical field at this site may be limited due to the close proximity to vital structures, which can lead to positive surgical margins.
14 Thus, wider surgical margins may be warranted.
Because positive surgical margins are often encountered in high-grade tumors, 22, 23, 27, 28 additional surgery would probably fail to improve the margins but could compromise vital structures. Furthermore, for high-grade tumors, such as ACC, postoperative RT is usually scheduled in the presence of additional adverse factors, such as T3 to T4 tumors, incomplete resection, and bone or perineural invasion. 25, 29 Postoperative RT increases local control of ACC, even in the presence of a residual tumor, although RT may also merely delay recurrence, which often occurs late during follow-up. 28 In this study, postoperative RT was administered for 60% of patients, of whom 87% were thought to have a high-grade tumor. The addition of RT was often warranted despite additional surgery. Chemotherapy is mainly restricted to locally recurrent or distant metastatic disease, 30, 31 although CRT may not improve survival. [32] [33] [34] Still, contradictory results have been reported. 35, 36 Thus, postoperative CRT, usually including cisplatin, has also been used in the treatment of high-risk salivary gland carcinomas, of which the ongoing clinical trial Radiation Therapy Oncology Group 1008 should provide new insight. 37 Postoperative chemotherapy is recommended for salivary duct carcinoma, which carries a high risk for distant metastasis, even without a clear distant control or survival benefit. 22 Additionally, among older patients, adjuvant
CRT carries more toxicity and mortality than RT alone. 38 Gao et al 39 reported that neither surgery nor oncologic treatment significantly impacted survival among patients with ACC with distant metastasis. Androgen deprivation therapy [40] [41] [42] [43] and targeted human epidermal growth factor receptor 2 therapy 40, 44 for salivary duct carcinoma may prove beneficial. Anti-epidermal growth factor receptor therapy, especially in ACC, has been shown to stabilize disease progression in patients with relapse or metastases. 45 Targeted therapy was utilized in 3 recurrent tumors in our cohort. In our cohort, 44% of patients experienced a recurrence during follow-up, and 28% incurred distant metastasis without recurrence at the locoregional site. Other researchers reported an opposite finding. Furthermore, a study by Armstrong et al 49 noted a higher incidence of occult metastases in submandibular gland tumors (21%) than in parotid gland tumors (9%). Additionally, the occurrence of distant metastasis in submandibular gland tumors (37%-42%) seems higher than in parotid gland tumors (17%-29%).
39,47

| C ONCL US I ONS
Clinical examination, preoperative imaging, and cytology may reveal no signs of malignancy or indicate benign findings in submandibular gland tumors that turn out malignant. Additionally, the lengthy time interval before the patient seeks medical attention may not raise the suspicion of malignancy. Utilizing FNAC, MRI, frozen section, and including level IB in the surgical field for inconclusive cases may assist in achieving an optimal extent of surgery. Routine extensive END does not seem advisable because occult metastases are rare and most malignant tumors are ACCs. In general, however, the higher propensity of submandibular gland tumors to metastasize to the neck compared with parotid gland tumors requires careful consideration. Due to the heterogeneity of submandibular gland malignancies, including the higher rate of distant metastasis, their evaluation and treatment must be individually tailored and centralized at experienced head and neck centers.
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